Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors

被引:40
作者
Teixeira, C. [1 ]
Serradji, N. [1 ]
Maurel, F. [1 ]
Barbault, F. [1 ]
机构
[1] Univ Paris Diderot, Lab ITODYS, F-75013 Paris, France
关键词
gp120; inhibitors; 3D-QSAR; CoMFA; CoMSIA; Docking; MOLECULAR SIMILARITY INDEXES; ENVELOPE GLYCOPROTEIN; VIRAL ENVELOPE; ARGININE CONJUGATE; ANALYSIS COMSIA; CD4; RECEPTOR; BINDING; BMS-378806; DYNAMICS; FUSION;
D O I
10.1016/j.ejmech.2009.03.028
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. Recently, 36 analogs compounds of BMS-806 were synthesized and their biological activity evaluated. Based on these compounds, a molecular docking was firstly performed with BMS-806 to the gp120 cavity in order to get a representative ligand conformation for the 3D-QSAR process. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were then conducted for these 36 compounds. CoMFA and CoMSIA models give reliable correlative and predictive abilities but the CoMFA model performance was slightly better than CoMSIA. CoMFA contours were analysed and have been correlated to the gp120 viral protein. The discussion indicates several key fragment positions on the ligands and their implications on the gp120 protein binding. The computational approach used in this paper provides reliable clues for further design of small molecules gp120/CD4 inhibitors based on the BMS-806. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:3524 / 3532
页数:9
相关论文
共 37 条
[1]  
BOHM M, 1994, J MED CHEM, V37
[2]  
Borkow G., 2005, Current Drug Targets - Infectious Disorders, V5, P3, DOI 10.2174/1568005053174645
[3]   3D QSAR investigations on antimalarial naphthylisoquinoline alkaloids by comparative molecular similarity indices analysis (CoMSIA), based on different alignment approaches [J].
Bringmann, G ;
Rummey, C .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (01) :304-316
[4]   Anti-HIV activity of a novel aminoglycoside-arginine conjugate [J].
Cabrera, C ;
Gutiérrez, A ;
Barretina, J ;
Blanco, J ;
Litovchick, A ;
Lapidot, A ;
Clotet, B ;
Esté, JA .
ANTIVIRAL RESEARCH, 2002, 53 (01) :1-8
[5]  
Case D.A., 2006, AMBER
[6]   The Tat antagonist neomycin B hexa-arginine conjugate inhibits gp-120-induced death of human neuroblastoma cells [J].
Catani, MV ;
Corasaniti, MT ;
Ranalli, M ;
Amantea, D ;
Litovchick, A ;
Lapidot, A ;
Melino, G .
JOURNAL OF NEUROCHEMISTRY, 2003, 84 (06) :1237-1245
[7]   CROSS-VALIDATED R(2)-GUIDED REGION SELECTION FOR COMPARATIVE MOLECULAR-FIELD ANALYSIS - A SIMPLE METHOD TO ACHIEVE CONSISTENT RESULTS [J].
CHO, SJ ;
TROPSHA, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (07) :1060-1066
[8]   Mechanism of membrane fusion by viral envelope proteins [J].
Harrison, SC .
VIRUS STRUCTURE AND ASSEMBLY, 2005, 64 :231-261
[9]  
HAWKINS GD, 1996, J PHYS CHEM, V100
[10]   Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates [J].
Hegde, Ravi ;
Borkow, Gadi ;
Berchanski, Alexander ;
Lapidot, Aviva .
FEBS JOURNAL, 2007, 274 (24) :6523-6536